Immune recognition of gene-modified cells severely limits the success of gene therapy. Therefore, the development of novel approaches to induce transgenetolerance is essential for successful gene-therapy trials. Enhanced green fluorescent protein (EGFP) is frequently used as a marker/model transgene in experimental genetherapy (bone marrow), transplantation and tumor models, and indeed, immune responses against EGFP can interfere in these models by clearing EGFP-expressing cells. [1] [2] [3] [4] Conversely, the immunogenic potential of a transgene such as EGFP can be exploited to establish immunological tolerance or to induce deletion of EGFPspecific cytotoxic T cells by using EGFP-transduced hematopoietic cells 3, 5 or splenic B cells, 4 thereby preventing rejection of gene-transduced cells/tissues. The immunogenicity of a transgene product is influenced by numerous factors such as the nature of the product, the vector, the target cell, the local microenvironment as well as the genetic and immunologic background of the host. In experimental mouse models, the immunogenicity of EGFP is well described in BALB/c mice, 2 and the immunodominant H2-K d -restricted cytotoxic T lymphocyte (CTL) epitope of EGFP has been identified in this strain. 6 However, the immunogenicity of EGFP in C57BL/6 is still a matter of debate. [2] [3] [4] 7, 8 In several studies using tumor-rejection models, minimal or no immunogenicity of EGFP was reported in C57BL/6 mice, 7, 8 whereas in other studies, reduced tumor growth of EGFP-transgenic tumor cells or enhanced rejection of EGFP-transgenic skin grafts was observed.
2,3 Similar as in BALB/c mice, engrafting EGFP-transduced hematopoietic cells in C57BL/6 mice results in tolerance to EGFP-transgenic skin grafts. 3, 5 Thus, although EGFP is clearly less immunogenic in C57BL/6 mice as compared with BALB/c mice, significant immune responses and tolerance to EGFP can be induced in C57BL/6 mice. This offers unique possibilities to study immunomodulatory strategies to less immunogenic transgene products in well-defined model systems. To facilitate such studies, we identified the immunodominant CTL epitope of EGFP in C57BL/6 mice. By using the BIMAS algorithm, + T cells in response to individual peptides was analyzed ex vivo by intracellular cytokine staining (BD Biosciences, Franklin Lakes, NJ, USA). Mice (n ¼ 4 per group) were immunized with a pool of six predicted EGFP peptides (50 mg of each peptide/mouse) in IFA combined with three intravenous injections (days 0, 1 and 2) of 50 mg a-CD40 (FGK45) antibody/mouse (Alexis Biochemicals, Lausen, Switzerland). After 14 days, mice were boosted intravenously with 1 Â 10 6 mature EGFP-expressing dendritic cells derived from Act-EGFP mice (EGFP-DC) and 1 week later, splenocytes were isolated, restimulated for 4 h with the individual peptides (1 mg ml À1 ) and IFN-g production by CD8 + T cells was analyzed. Mature EGFP-DCs were obtained by culturing bone marrow cells of Act-GFP mice (Jackson Laboratories, Bar Harbor, ME, USA) for 7 days in the presence of 20 ng ml À1 granulocyte macrophage colony-stimulating factor and 10 mg ml À1 lipopolysaccharide, added 16 h before injection to induce maturation. (c) Mice (n ¼ 4 per group) were immunized and boosted with 1 Â 10 6 matured bone marrow-derived EGFP-DCs on days 0 and 14. On day 21, splenocytes were isolated and specific IFN-g production by CD8
+ T cells was assessed (as described in b) . EGFP, enhanced green fluorescent protein; IFN-g, interferon-g. (Figure 1a) . To analyze the ability of these peptides to induce CTL responses in vivo, C57BL/6 mice were immunized with a peptide pool containing the six predicted EGFP peptides in Incomplete Freund's adjuvant (IFA) (Difco Laboratories, Detroit, MI, USA) together with a-CD40 antibody. Mice were boosted with mature EGFP-expressing dendritic cells and 1 week later splenocytes were isolated and interferon-g (IFN-g) production by CD8 + T cells was analyzed ex vivo in response to the individual peptides. Only peptide EGFP 118-126 induced IFN-g production by CD8
+ T cells freshly isolated from immunized mice (Figure 1b) . This EGFP 118-126 epitope is also endogenously processed and presented by EGFP-expressing cells, since specific IFN-g production was observed by spleen-derived CD8 + T cells in response to EGFP 118-126 after injection of mice with mature EGFP-expressing dendritic cells (Figure 1c) . Thus, EGFP 118-126 is a naturally occurring EGFP epitope able to induce CTL responses in C57BL/6 mice.
We believe that the identification of this EGFP epitope in C57BL/6 mice will be very useful for researchers developing and monitoring strategies for interference with the immune response to (weak) immunogenic gene therapy-derived products.
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